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Abstract  
Alzheimer's disease (AD) is the most common form of dementia characterized by substantial 
neuronal loss and progressive brain atrophy. Animal studies have suggested that the process of adult 
neurogenesis might be altered at the earliest phases of disease onset. The relationship between AD 
progression and adult neurogenesis in the human brain is, however, not well understood. Here, we 
present a systematic review of the post-mortem studies that investigated changes in human adult 
neurogenesis in the AD brain. We present findings from 11 post-mortem studies that were identified 
by a systematic search within the literature, focusing on what markers of neurogenesis were used, 
which stages of AD were investigated, and whether the studies had any confounding information 
that could potentially hinder clear interpretation of the presented data. In addition, we also review 
studies that examined transcriptomic changes in human AD post-mortem brains and reveal 
upregulated expression of neural progenitor and proliferation markers and downregulated 
expression of later neurogenic markers in AD. Taken together, the existing literature seem to suggest 
that the overall level of human adult neurogenesis is reduced during the later stages of AD, 
potentially due to failed maturation and integration of new-born neurons. Further investigations 
using complementary methods such as in vitro disease modelling will be helpful to understand the 
exact molecular mechanisms underlying such pattern of change and to determine whether 
neurogenesis can be an effective therapeutic target for early intervention. 
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1. Introduction 
Alzheimer's disease (AD) is the most common form of dementia and no disease-modifying therapies 
are currently available. Extracellular amyloid plaques and intracellular neurofibrillary tangles are 
neuropathological hallmarks of AD. The degree of pathology can be measured by following Braak 
stages, which traces the progression of neurofibrillary tangles from the transentorhinal regions (Braak 
I-II), to the limbic regions including the hippocampal formation (Braak III-IV), and then to the 
neocortical regions (Braak V-VI) (Braak and Braak, 1991; Braak et al., 1993). These stages further relate 
to the emergence of atrophy in the hippocampal formation, which is one of the most salient and 
earliest features of AD, and they also correlate with the progression of neuronal loss observed in the 
respective areas as well as memory loss (Bancher et al., 1993). 
Since adult neurogenesis is implicated in normal functionality of hippocampal circuits (Marin-Burgin 
and Schinder, 2012), impaired neurogenesis may detrimentally affect the survival of adult-born 
neurons and contribute to defects in learning and memory observed in AD by reducing brain plasticity 
(Gadadhar et al., 2011). Furthermore, rodent studies have shown that several molecular factors 
important for AD pathogenesis, such as amyloid precursor protein (APP), presenilin 1 (PSEN), and 
apolipoprotein E (APOE), also play a key role in modulating adult hippocampal neurogenesis, 
suggesting that dysregulation of neurogenesis might be an important aspect of AD progression (Mu 
and Gage, 2011). 
Adult mammalian endogenous neurogenesis occurs predominantly in the hippocampal dentate gyrus 
(DG) and in the subventricular zone (SVZ) situated throughout the lateral ventricle walls. 
Type I neural stem cells originating in the subgranular zone (SGZ) in the DG give rise to type IIa/IIb 
neural progenitor cells and type III neuroblasts which eventually integrate in the neural network 
forming the granular cell layer (Fig. 1). Functionally, neurogenesis in the DG has been shown to be 
crucial for hippocampal dependent learning and memory including conjunctive encoding, pattern 
separation, pattern completion, and spatial navigation in rodent models (Lazarov and Hollands, 2016). 
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Neurogenic remodeling of hippocampal circuitry is also thought to play an important role in both 
memory persistence and transience in rodents (Richards and Frankland, 2017). 
In the SVZ, type A cells are present in a layer found immediately beneath the ependymal cell layer 
(ECL) and represent the migrating neuroblasts. Type B cells are GFAP positive and represent the 
primary progenitors while type C are known as the transient amplifying cells. In rodents, the neural 
progenitors originating at the SVZ follow the rostral migratory stream (RMS) into the olfactory bulb 
(OB) (Fig. 1) where they develop into interneurons of granule cells or periglomerular cells (Lazarov and 
Hollands, 2016). Studies have suggested that in humans, SVZ-derived neuroblasts might be migrating 
to the adjacent striatum, also a region of importance for cognitive flexibility (Bergmann et al., 2015). 
Endogenous neurogenesis has been generally shown to persist throughout adulthood, and its levels 
can drop significantly with normal aging in various mammals including rodents (Knoth et al., 2010; 
Kuhn et al., 1996) and non-human primates (Leuner et al., 2007), correlating with age-related 
cognitive decline and memory loss. 
Expanding this knowledge onto humans, several studies have shown that postnatal neurogenesis 
also persists in the adult human brain throughout life, primarily in the hippocampus (Eriksson et al., 
1998; Spalding et al., 2013). However, recent findings from postmortem human brain tissues have 
reported contradicting findings, where one study suggested that human hippocampal neurogenesis 
declines sharply to undetectable levels in adults after the first year of life (Sorrells et al., 2018), and 
the other study reported that endogenous neurogenesis does continue throughout aging with no 
significant changes in the pools of progenitor cells and immature neurons (Boldrini et al., 2018). 
Although several lines of evidence generally seem to support the prevailing view on the existence of 
human adult neurogenesis, the discrepancy of these findings point to the limitations in our current 
understanding of human hippocampal neurogenesis and suggest room for improvement 
(Kempermann et al., 2018; Lee and Thuret, 2018). 
Most of our current understanding of in vivo adult neurogenesis has been derived from non-human 
animal models which helped us to identify cellular markers that can be used to label different types 
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of cells at each stage of neurogenesis. In postnatal hippocampal neurogenesis, for example, these 
markers include glial fibrillary acidic protein (GFAP) and Nestin (type I neural stem cells), 
doublecortin (DCX) and polysialic acid neural cell adhesion molecule (PSA-NCAM) (type IIa/IIb neural 
progenitor cells and type III neuroblasts), and prospero homeobox 1 (PROX1) (immature and mature 
dentate gyrus granule cells). The expression patterns of these markers are known to be well 
conserved across different species and have therefore been extrapolated to represent stages of 
neurogenesis in human post-mortem studies. However, the use of these ‘proxy’ markers of 
neurogenesis may be caveated by several factors: cells tend to express multiple markers at a given 
time; markers may be sensitive to post-mortem delay; there are variations in methods of cell 
quantification, and lastly none of these markers have yet been validated in human samples. These 
limitations are highlighted and discussed in more detail within this review. In anticipation of human-
verified markers of neurogenesis, we here in present a transcriptomic analysis of several human AD 
profiles which complements the immunostaining studies reviewed. 
It is unclear whether promotion of endogenous neurogenesis may be a directly relevant treatment 
target per se in AD, since it is unlikely that a small number of newly generated neurons might have a 
large enough effect to repair the damage and regenerate the degenerated neurons in late-stage AD. 
However, it might be possible that a small pool of new neurons generated at the early stages of AD 
exert enough support to prevent or slow down severe cognitive decline by contributing directly to 
the enhancement of memory function (Deng et al., 2010). Implantation of human cortical stem cells 
in rodent models of stroke has been shown to induce endogenous neurogenesis and promote 
angiogenesis and trophic factor release (Hassani et al., 2012; Hicks et al., 2013) and it would be 
interesting to investigate whether promotion of endogenous neurogenesis could confer similar 
benefits. Furthermore, several studies have shown that physical activity, environmental enrichment 
and higher levels of education promote hippocampal neurogenesis as well as improve memory  (Mu 
and Gage, 2011; Rodríguez and Verkhratsky, 2011). Such findings might suggest that maintenance of 
endogenous neurogenesis throughout adulthood might contribute to cognitive resilience in AD. 
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In this systematic review, we discuss findings from studies that have investigated changes in human 
adult neurogenesis in AD by collating all relevant data generated from human post-mortem studies 
that can be found in the existing literature. We summarize their findings primarily focusing on the 
neurogenesis markers that were used to measure the relative changes in the AD brain compared to 
controls. We also discuss the findings in relation to AD stage of progression and any possible 
confounding factors that might have been introduced to the studies. 
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2. Material and Methods 
2.1 Systematic Search 
Following the International Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) guidelines (Moher et al., 2009), we undertook a systematic search for literature indexed in 
Medline and Embase up to 18th of June 2018. Full search terms utilized in the individual databases 
are shown in supplementary material (S1). 
Relevant literature reviews (von Bohlen Und Halbach, 2007, 2011) were used as guides in selecting 
appropriate neurogenic and proliferation markers which identify the different stages of neurogenesis. 
The possible aliases and search terms for these individual markers were then identified using 
GeneCards (www.genecards.org (Stelzer et al., 2016)), and are shown in S1 and described in Box1. 
Since the aim of this review is to investigate neurogenesis in AD, articles investigating the expression 
of proliferation markers (Ki67 and PCNA) were only included if they also investigated the expression 
of at least one neurogenic marker listed in Box1. 
Only peer-reviewed primary research articles written in the English language were considered. 
Reviews and conference abstracts were excluded. Articles passed the inclusion criteria if they: 1) were 
carried out with post-mortem brain samples of AD 2) measured the expression of neurogenic markers 
listed in Box1 in the neurogenic niches of the brain (SVZ and SGZ) and 3) were compared with non-
demented controls. References of resulting articles were searched for additional relevant studies. 
Retained articles were evaluated against the inclusion criteria by a second independent reviewer 
(H.L.). Data was manually extracted from the studies and is listed in table 1. Overall results extracted 
from the different studies are shown in matrix form in Table 2. The terms higher (↑), lower (↓) or 
unchanged (↔) used in table 1 and 2 refer to the corresponding changes in expression of neurogenic 
or proliferation markers relative to the control group within the study, as identified by the authors of 
the study themselves. 
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Due to the variability in techniques and outcome measures in these studies, a relevant meta-analysis 
or other statistical summary is not reported here. 
2.2 The meta-AD transcriptional profile 
A total of 30 independent AD profiles were generated from published transcriptional data (Gene 
Expression Omnibus (GEO) database (Barrett et al., 2013)), and a meta-AD profile was generated 
that consists of a list of genes with the corresponding sum of up/down (counted as +/- 1) regulation 
calls across these profiles (Supplemental material Table S1-3, Fig.3A-C). The effects of different brain 
regions were controlled for by treating it as a categorical covariate when combining data from 
different brain regions. 
In addition to looking at a panel of AD profiles, we examined a set of expression data corresponding 
to a range of clinical dementia ratings (CDR) (GSE84422 – 19 brain regions from 125 individuals (Wang 
et al., 2016) and another set of expression data corresponding to a range of Mini-Mental State 
Examination (MMSE) scores (GSE1297 - hippocampi from 31 individuals (Blalock et al., 2004). Here, 
we performed a linear mixed model for each gene probe to see which genes best explain cognitive 
decline while treating brain region, sex and race as covariates where given. The numbers given are the 
Z-scores associated with the correlation between gene expression and cognition score (Supplemental 
material Table S4-6, Fig.3D-F). Further, we assessed to what extent genes whose expression explained 
the decline in cognition were also seen to vary in expression across a panel of AD profiles. 
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3. Results 
The database searches identified 1661 potential articles, of which 50 potentially met the inclusion 
criteria based on the title and abstract, but only 8 fully met all inclusion criteria. An additional 3 articles 
were identified from the references of these 8 studies, yielding a total of 11 articles included in the 
current systematic review (Fig. 2.). To be able to interpret the findings appropriately, the conclusions 
from the individual articles will be presented according to the neurogenic stage which the markers 
used identify (Fig.1.). 
3.1 Stage 1 (proliferation) and stage 2 (differentiation)–GFAP, Msi-1, SOX2, Nestin 
Seven articles investigated changes in stage 1 and stage 2 markers. Two studies reported an 
upregulated expression of the astrocytic marker GFAP, expressed in the radial-glia-like stem cells, in 
the DG in the severe stages of AD (Braak V-VI) (Boekhoorn et al., 2006; Ekonomou et al., 2015). GFAP 
expression was, however, reduced in Braak stages III-IV, suggesting reduced glial support in the earlier 
disease stages (Ekonomou et al., 2015). 
Expression of Msi-1, a marker of undifferentiated, proliferative cells, was upregulated in the DG in 
Braak stage II and downregulated in Braak stage IV and VI (Perry et al., 2012).  Downregulated 
expression of Msi-1 was also observed in the later disease stages in AD SVZ (Perry et al., 2012; Ziabreva 
et al., 2006); but only reached statistical significant difference in one study (Ziabreva et al., 2006). 
Importantly, both studies (Perry et al., 2012; Ziabreva et al., 2006) reported a correlation of Msi-1 
expression with choline acetyltransferase (ChAT) immunoreactivity suggesting a link between reduced 
cholinergic activity and reduced progenitor number. 
Expression of the neural stem cell marker SOX2 was significantly reduced in the DG in Braak stage VI 
in two studies (Briley et al., 2016; Crews et al., 2010) whilst another study reported no change in SOX2 
expression in the AD DG (Gomez-Nicola et al., 2014). However, the disease stage investigated, or 
extent of pathology were not presented in the latter manuscript. Interestingly a study investigating 
neurogenic changes in AD and non-demented patients with Alzheimer’s neuropathology (NDAN), 
Gatt et al. 10 
 
found that SOX2+ cells were more abundant in NDAN DG compared to AD or MCI patient DGs (Briley 
et al., 2016) . Consistently with the Boekhoorn study, AD patient DG exhibited reduced numbers of 
SOX2+ cells, suggesting a reduction in the number of neural stem cells in AD (Braak stage VI). SOX2 
expression was, however, elevated in the DG of both MCI (Braak stage II-V) and NDAN patient groups 
(Braak stage IV-VI) when compared to controls. 
Importantly, these authors found that a percentage of cells in the human DG were expressing both 
SOX2 and the late postmitotic marker NeuN. AD patient DG exhibited reduced numbers of 
SOX2+/NeuN- cells as well as SOX2+/NeuN+ cells, suggesting a reduction in the number of both neural 
stem cells as well as mature postmitotic neurons in AD. Conversely, MCI patients exhibited increased 
SOX2+/NeuN- cells and decreased SOX2+/NeuN+ cells whilst in NDAN individuals, both SOX2+/NeuN- 
cells as well as SOX2+/NeuN+ cells were increased when compared to controls (Briley et al., 2016). 
This suggests that NDAN individuals hold higher potential for not only generating more neural stem 
cells, but also for these cells to survive long enough to become mature neurons, whilst AD individuals 
have reduced numbers of stem cells as well as a reduced number of postmitotic neurons. 
Expression of the neural stem/progenitor cell marker Nestin was unchanged in the AD ependymal cell 
layer (ECL) of the SVZ in two studies (Ekonomou et al., 2015; Ziabreva et al., 2006), and increased in 
higher Braak stages in AD SVZ  (Perry et al., 2012; Ziabreva et al., 2006), SGL and GL (Perry et al., 2012). 
This increased expression might not necessarily indicate increased migration or targeting, as 
expression of DCX and B-tubulin remained unchanged in the subgranular and granular layers of the 
DG (Perry et al., 2012) . A later study found no such changes in Nestin expression in the SVZ or in the 
DG throughout different Braak stages (Ekonomou et al., 2015). It is unclear whether the changes 
observed by Perry could have been due to re-induced Nestin expression in glial cells following 
neurotoxicity, as has been previously reported (von Bohlen und Halbach, 2011). 
 
3.2 Stage 3 (migration) –PSA-NCAM, DCX, TUC-4/CRMP-4 
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Once immature neurons commit to a neuronal lineage, they stop expressing Nestin and start 
expressing PSA-NCAM and Doublecortin (DCX). A total of nine articles investigated the expression of 
stage 3 markers. 
In one study, total NCAM expression in AD brains was similar to controls in both its polysialylated form 
and other forms (Gillian et al., 1994). The cohort sizes used, however, were relatively small and the 
disease severity was not reported. Later studies found that PSA-NCAM immunoreactivity was 
significantly higher in AD SGL and GL (Jin et al., 2004b; Mikkonen et al., 1999; Perry et al., 2012). 
In one of the first studies focused on investigating neurogenesis in AD, PSA-NCAM, DCX and TUC-
4(/CRMP-4) expression were found to be increased in the hippocampi of AD when examined by 
western blotting, correlating with AD severity (Jin et al., 2004b). The upregulation of DCX and TUC-4 
in the AD GL was also verified by immunohistochemical analysis. While this was a pioneering study in 
terms of the range of neurogenic markers studied in the AD brain, it did present a number of caveats: 
the cohort numbers were relatively small; the control cases in the western blot analysis were much 
younger than AD cases; and the disease severity and gender of AD cases were unknown. 
Two later studies also observed an overall increased expression of DCX in the later AD stages in the 
DG (Ekonomou et al., 2015; Perry et al., 2012), whilst another study reported reduced expression of 
DCX in the DG of AD (Braak VI) compared to non-demented controls and Braak stages I-II  (Crews et 
al., 2010). Another study found no difference in DCX expression in DG of presenile AD, and reported 
high variability in the numbers of DCX-positive granular elements between subjects (Boekhoorn et al., 
2006). DCX is considered a marker for late mitotic neuronal precursors and early postmitotic neurons. 
However, it has also been reported to label astrocytes (Verwer et al., 2007) and dormant cells (Kremer 
et al., 2013; Marti-Mengual et al., 2013) in non-neurogenic regions. Furthermore, DCX expression is 
particularly sensitive to post-mortem delay (Boekhoorn et al., 2006), which is a factor that inevitably 
differs greatly between the five studies that investigated it (ranging between an average of 5h 
Gatt et al. 12 
 
(Boekhoorn et al., 2006) to 17.5h (Ekonomou et al., 2015) in the AD groups). These results therefore 
need to be interpreted with caution. 
3.3 Stages 4 (axonal and dendritic targeting) and 5 (Synaptic integration) – Calretinin, NeuN, Calbindin, 
β-III-tubulin, MAP2a,b,c, HuC/D 
Once the newly generated neurons become postmitotic they start transiently expressing the calcium-
binding protein calretinin and the widely used neuronal marker NeuN. After approximately 2-3 weeks 
in this postmitotic stage, calretinin is exchanged for calbindin in mature granule cells, which 
functionally integrate in the hippocampus. NeuN expression is sustained in these mature cells. Six 
articles investigated the expression of stage 4 and 5 markers. 
One study, which did not provide information regarding disease stage, reported upregulated labelling 
of Calretinin in the AD DG (Gomez-Nicola et al., 2014). Expression of Calbindin and NeuN was found 
to be unchanged in the AD hippocampal region via western blot analysis (Jin et al., 2004b) and β-III-
tubulin expression was also unchanged in AD SVZ and DG in another study (Perry et al., 2012) . 
Expression of MAP2c was also unchanged in an additional study (Li et al., 2008), whilst expression of 
MAP2a,b isoforms was significantly decreased in AD DG, suggesting that it is the maturation of 
neurons that is being compromised (Li et al., 2008). 
Expression of the neuronal marker protein HuC/D was decreased in the DG of late Braak AD stages, 
however, double PCNA/HuC/D immunolabelling was unchanged suggesting that there was no overall 
change in neural progenitors (Ekonomou et al., 2015). 
3.4 Proliferation markers – Ki67, PCNA 
PCNA is also expressed in non-neuronal cells and has previously been shown to be upregulated in AD 
glial cells with a trend towards increased expression correlating with increased AD pathology, along 
with Ki-67 (Wharton et al., 2005). Within the articles included in this review, two studies have 
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demonstrated elevated Ki-67 expression in the AD hippocampus (Boekhoorn et al., 2006; Gomez-
Nicola et al., 2014) suggesting that overall proliferation might be elevated in AD. 
3.5 Filtration of articles 
Since the articles herein reviewed were of variable quality and in some cases exhibited contrasting 
results, we further filtered the search to collate the articles that included the most information we 
deemed relevant to the question at hand (Table 3). The filtering criteria we set to assess quality of the 
publication were related to 1) whether control cases were defined and age-matched to the AD cases, 
2) whether a disease severity scale (Braak stage) was reported, 3) whether multiple neurogenic or 
proliferation markers were investigated and 4) whether any confounding pathologies were discussed. 
Overall, only two articles (Boekhoorn et al., 2006; Ekonomou et al., 2015) passed all four filtering 
criteria. 
Both articles reported an upregulated expression of GFAP suggesting extensive astrogliosis in severe 
AD (Braak stage V-VI). The Ekonomou study, however, also reported reduced GFAP expression in Braak 
stages III-IV (Ekonomou et al., 2015). Since GFAP identifies both neural stem cells and astrocytes it is 
difficult to determine whether this Braak stage variability suggests a differential neurogenesis or 
gliogenesis in different stages of AD. Ekonomou reported no change in expression of the early neural 
precursor Nestin in AD (Ekonomou et al., 2015). The two studies report conflicting findings in relation 
to DCX expression with Boekhoorn being unable to draw any conclusions from the data and Ekonomou 
suggesting that DCX-positive cells were more common in DG of individuals with higher Braak stages 
(Boekhoorn et al., 2006; Ekonomou et al., 2011). However, both studies adamantly report that DCX 
expression was too low and variable to draw significant conclusions. Ekonomou et al., also detected a 
lower number of HuC/D-positive postmitotic early neurons in the DG in individuals with higher Braak 
stages, whilst double immunolabelling of HuC/D-PCNA was unchanged suggesting no alteration in the 
number of neural progenitors in AD (Ekonomou et al., 2015). 
3.6 Transcriptional changes in neurogenic/proliferation markers in AD 
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To validate the alterations in levels of expression of neurogenic and proliferation markers in AD, we 
investigated differences at the transcriptional level. To this end, human AD post-mortem studies 
deposited in the NCBI GEO database (www.ncbi.nlm.nih.gov/geo/) were collected by querying the 
series repository with ‘Alzheimer’s’ as key term and restricting the output to human brain sample 
data. This resulted in a total of 30 independent AD profiles generated from 11 expression series. 
Significance was assessed with a student’s t-test on the difference between the AD and healthy 
subsets. Probes were assigned to genes, and the probe with the largest expression change was 
selected from AD subsets. The expression change values shown in supplementary tables (Table S1-6) 
are scaled according to 2(𝑑 − 𝑐)/(𝑑 + 𝑐), where d and c are the average disease and control levels 
(Fig.3.). Significant expression changes below 25% were taken to be biologically irrelevant and 
dropped from subsequent analysis. 
A meta-AD profile was created by summing the up and down calls on each gene across the expression 
set (Table S1, Fig. 4A). This profile demonstrates that throughout the different AD studies, expression 
of neural progenitor markers and the cell proliferation marker, MKI67, were upregulated whilst 
expression of the later neurogenic markers was mainly downregulated. The meta-AD profile was then 
restricted to a set of 13 studies that investigated the hippocampus and further subdivided into studies 
investigating transcriptomic changes in early AD and late AD. AD severity was defined as identified by 
the individual studies themselves. Only eight markers appeared to be altered in the early AD stage, 
corresponding to a handful of studies (Table S2, Fig.4B), whilst the majority of late AD studies 
demonstrated upregulation of neural progenitor markers and downregulation of later neurogenic 
markers (Table S3, Fig. 4C).  
Although there were fewer datasets that reported cognitive measure outcomes such as MMSE and 
CDR scores alongside transcriptomics data, we nevertheless decided to investigate to what extent 
gene expression changes in neurogenic markers can explain cognitive decline. Analysis of a study 
investigating the correlation of gene expression with MMSE scores (GEO accession GSE1297 (Blalock 
Gatt et al. 15 
 
et al., 2004)), identified GFAP and MK167 as significant anti-correlative predictors of MMSE, where 
the genes are correlated with moderate cognitive decline (MMSE>15) and mild cognitive decline 
(MMSE>20), respectively. Expression levels of NEUROD1, NEUROD6, CRMP1, TUBB, ELAVL4 were 
positively correlated with MMSE, and therefore, negatively correlated with AD. NEUROD6 was 
identified as a significant predictor of moderate cognitive decline (MMSE>15) (Table S4, Fig. 4D.). An 
additional study (GEO accession GSE84422 (Wang et al., 2016)) was investigated as it covered a wide 
range of brain regions in a large cohort of individuals with a full range of Clinical Dementia Rating 
(CDR) scores (0-5). The expression of neural progenitor markers (VIM, MSI1, NES), GFAP, and MKI67 
were positively correlated whilst most of the later neurogenic markers (NEUROD2, NEUROD6, CRMP1, 
NCAM1, DCX, TUBB, CALB1, MAP2, ELAVL2, ELAVL4, RBFOX3) were negatively correlated with CDR 
(Table S5, Fig.4E). A similar result was observed in an analysis restricted to a CDR score of less than 2 
(Table S6, Fig.4F). Taken together, our analysis validates significant changes in expression of 
neurogenic markers in the AD brain, including the hippocampal region, and suggests that these 
expression changes are correlated with cognitive decline. 
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4.Discussion 
A systematic review presented in this study suggest that neurogenesis is reduced in the later stages 
of AD. We find that expression of neural progenitor and proliferation markers is transcriptionally 
upregulated whilst that of later neurogenic markers is downregulated in the hippocampus of late AD 
brains. Based on these findings, we propose the hypothesis that neurogenesis is reduced in late AD 
due to failed maturation and integration of new neurons. 
Studies of adult neurogenesis in rodent models of AD have yielded contradictory findings, with some 
studies suggesting a reduction in proliferation (Demars et al., 2010), survival (Verret et al., 2007), and 
maturation (Li et al., 2009) of new-born neurons and others suggesting increased proliferation and 
differentiation of the same cells (Jin et al., 2004a; Lopez-Toledano and Shelanski, 2007) [for a more 
detailed review, see (Mu and Gage, 2011)]. Interestingly, a study investigating the different stages of 
neurogenesis in different stages of neurodegeneration in PS1/PS2 knockout mice, found that levels of 
neurogenesis in the DG are directly correlated to the severity of neuronal loss in the hippocampus. 
Furthermore, whilst early neurodegeneration triggered an upregulation of adult neurogenesis in this 
study, late-stage neurodegeneration led to the downregulation of the process, which is in line with 
the overall findings from this systematic review (Chen 2008).  
4.1 Neuronal maturation is compromised in AD 
According to the studies reviewed here, there is a distinction between the expression of neurogenic 
and glial markers in AD, with greater compromise in neuronal maturation. Both IHC and transcriptomic 
studies suggest that expression of markers/genes associated with neuronal maturation are 
downregulated in AD. Interestingly, a recently published study reported similar findings in a normal 
healthy brain (Mathews et al., 2017). The early and intermediate phases of neurogenesis were 
unchanged and stem cell pools remained consistent, while proliferation and number of mature 
neurons were reduced with aging, possibly due to alterations in the hippocampal microenvironment 
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which affect the expression of genes regulating maturation and migration of new neurons (Mathews 
et al., 2017). 
4.2 Neurogenic changes in the AD SVZ are not linked to changes in the AD DG 
Regional differences indicated that whilst most studies focused on neurogenic changes in the DG, only 
three IHC studies investigated changes in the SVZ (Ekonomou et al., 2015; Perry et al., 2012; Ziabreva 
et al., 2006), with the expression of the majority of neurogenic markers investigated being unchanged 
in AD SVZ compared to controls. Neurogenic changes in the AD SVZ are therefore still a point of debate 
and we suspect there is not enough information available to draw a conclusion regarding the matter. 
However, it appears that SVZ changes do not directly mirror changes in the DG and vice versa. 
4.3 Correlation between neurogenesis and cholinergic pathology 
Two of the studies reviewed exhibited a correlation between Msi-1 expression and ChAT 
immunoreactivity. Acetylcholine has been shown to promote the proliferation of neural stem cells 
and is known to mediate synaptic plasticity (Mitsushima et al., 2013) and is therefore a feasible 
regulator of neurogenesis. Animal studies have shown that lesions to the cholinergic basal forebrain 
neurons in adult rats led to reduced neurogenesis in the dentate gyrus and olfactory bulb, as well as 
increased apoptosis in the neurogenic regions of the rat brain, whilst systemic administration of a 
cholinergic agonist caused an increase in proliferation and short-term survival of neuronal progenitors 
in the rat DG (Mohapel et al., 2005). Importantly, an additional study observed ectopic expression of 
Msi-1 in a significant number of neurons containing cytoplasmic inclusions in severe AD, suggesting 
an involvement of the protein in the pathogenesis of the disease (Lovell and Markesbery, 2005). This 
finding could suggest that the observed correlation of Msi-1 expression and cholinergic pathology in 
AD neurogenic regions might not be a direct reflection of alterations in neurogenesis per se and such 
results should therefore be interpreted with caution. 
 
4.4 Correlation between neurogenesis and vascular pathology 
Gatt et al. 18 
 
In their study, Ekonomou et al., excluded any cases presenting with cerebrovascular pathology from 
their cohort (Ekonomou et al., 2015), whilst Boekhoorn et al., discussed any vascular associated 
changes within their findings (Boekhoorn et al., 2006). They found that Ki67 expression was elevated 
in AD specifically in areas of vascular pathology, however they specify that these proliferative changes 
are most likely to be representing aberrant and non-functional Ki67 expression and are therefore not 
defining neurogenesis (Boekhoorn et al., 2006). Several other studies have shown that neural 
progenitors are indeed increased in areas of cerebrovascular pathology in cases of Vascular dementia, 
cerebral small vessel disease, stroke, ischemic injury and cerebral infarction (Ekonomou et al., 2011; 
Ekonomou et al., 2012; Jin et al., 2006; Macas et al., 2006; Minger et al., 2007). Furthermore, neural 
progenitor cells in the SVZ migrate to the area of cerebrovascular injury (Arvidsson et al., 2002; 
Ekonomou et al., 2011) and are capable of differentiating into immature neurons (Ekonomou et al., 
2011). The remaining articles discussed in this review do not mention cerebrovascular pathologies in 
their cohorts. The factors regulating this mechanism are currently unknown, but such findings do 
suggest that vascular changes must be analysed when investigating neurogenic changes in AD. 
 
4.5 Differing methodologies, medications and changes in gliogenesis might contribute to variability 
observed in the studies 
The studies selected for this review exhibit some conflicting results which are difficult to interpret. 
Such variability in these studies might be related to cases exhibiting concurrent pathologies (such as 
vascular changes or Lewy body pathology), to only one antibody being used as a marker of 
endogenous neurogenesis, therefore only representing one stage of the process, and to numerous 
articles not relating their findings to disease severity (such as Braak staging). We chose to review 
articles in which IHC was the main technique utilized to look at changes in neurogenesis. Studies that 
do not take into account regional staining (as in western blot analysis (Jin et al., 2004b)) risk diluting 
out potential differences between AD and control tissues, whilst IHC takes into account heterogeneity 
in the brain and provides a region-specific outcome. Technical differences still contribute to the results 
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obtained between studies especially if different fixation times, antibodies and antigen retrieval 
methods are used. Moreover, the studies reviewed used different methods of quantifying 
immunoreactivity in their samples with some quantifying optical density or percentage area of 
immunoreactivity and others providing an actual cell count of immunopositive cells. 
None of the identified studies reported on the use of specific medications in controls or Alzheimer’s 
patients. Unreported medication use, especially if differing between controls and AD subjects, could 
be a potential confounding factor. Antidepressants are commonly prescribed to dementia patients 
and several studies have shown that treatment with antidepressants leads to improved neurogenesis 
(Boldrini et al., 2012; Boldrini et al., 2009; Gatt et al., 2018) including a recent study showing that SSRI 
treatment in DLB/PDD elevated DCX expression which, in turn, correlated with preserved cognition 
(Gatt et al., 2018). Similarly, alterations in neuroinflammation are related to neurogenesis (Fuster-
Matanzo et al., 2013) and nonsteroidal anti-inflammatory drug treatment has been shown to reduce 
the number of activated glial cells (Heneka et al., 2005; Mackenzie and Munoz, 1998). The role of 
astrocytes and microglia in modulating the neuroinflammatory response in AD has also been well 
investigated (Hopperton et al., 2018; Phillips et al., 2014). GFAP-positive glial cells play an important 
role in neurogenesis providing metabolic support, regulating synaptic formation and transmission, 
releasing trophic factors as well as playing an important role in neuroinflammation. Studies reviewed 
here have shown that GFAP immunoreactivity was increased in the more severe disease stages in AD. 
It is difficult to interpret whether GFAP expression elevation is due to increased gliogenesis or 
increased number of glia-like stem cells. It would be interesting to determine how GFAP expression 
relates to underlying pathological burden, and whether there is a therapeutic window in which 
microglial or astrocyte stimulation could be used to promote endogenous neurogenesis. 
Further, whilst Msi-1 and SOX2 expression appears to be downregulated in the IHC studies reviewed, 
transcriptional analyses revealed an upregulated expression of these genes in AD profiles. 
Contrastingly, DCX, Tuc-4 and NCAM expression was upregulated in IHC studies and downregulated in 
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AD transcriptional studies. It is difficult to interpret what could be causing these differences, however, 
as described above, there are numerous factors that question the use of Msi-1 and DCX as markers of 
neurogenesis in IHC which could partially explain the diverging findings. 
Overall, it is still unclear how underlying AD pathology affects the generation of new neurons in the 
adult brain, however, since a multitude of factors affect this process including neuroinflammation, 
vascular pathology and treatment with antidepressants, it is imperative for such confounding factors 
to be considered when investigating neurogenesis in AD postmortem tissue. 
4.6 Limitations and recommendations 
This review has important limitations. Using post-mortem tissue to investigate the expression of 
neurogenic markers is limited to the specific disease stage at which autopsy took place. Multiple 
labelling is therefore crucial to distinguish whether an increase in neural progenitors signifies an 
increase in mature neurons (and therefore neurogenesis) or whether these progenitors fail to mature 
to functional neurons. Furthermore, since several markers, such as DCX, are expressed by various cell 
types at multiple neurogenic stages, one must take care in comparing studies which focus on only one 
marker. The markers we have outlined as associated with neurogenesis were mainly identified as such, 
when studying neurogenesis in animal models. This is not an ideal scenario as several discrepancies 
exist in the expression of neurogenic markers in rodents compared to humans and extrapolating 
rodent findings to human studies has clear limitations. As Briley et al., observed in their study, SOX2 
expression overlaps with that of the neuronal marker NeuN in the human but not in the murine DG, 
where SOX2 expression is restricted to undifferentiated NSCs (Briley et al., 2016). Furthermore, it has 
been shown that animal neural stem cells can differ significantly from the human equivalent such as 
having different paces of maturation as demonstrated by Otani and colleagues (Otani et al., 2016), 
which leads to the possibility of different set of markers being expressed at different stages of 
neurogenesis, or even the same markers serving different functions at each stage. Taken together, 
these observations highlight that the field needs to establish a library of human-specific neurogenic 
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markers that are robust and clearly interpretable. One could perhaps start by trying to identify which 
markers are human-relevant through in vitro modelling of human neurogenesis stages from neural 
stem cells to mature functional neurons. For example, a time-course characterisation of human 
embryonic or induced pluripotent stem cells that are differentiating into hippocampal neurons could 
be done by analysing the whole transcriptome at a single-cell level. Given that several protocols for 
generating dentate gyrus granule cells and hippocampal pyramidal cells are already available in the 
literature (Sakaguchi et al., 2015; Sarkar et al., 2018; Yu et al., 2014), a single-cell analysis on the cell-
types generated during the differentiation process could be readily achieved. Such characterisation 
approach would not only help us to validate cell-type and stage-specific markers of human 
neurogenesis but also to develop an accurate understanding of how neurogenesis is affected in the 
disease context. 
The transcriptional profiles investigated in this review were not generated from single-cell 
transcriptomic analysis but rather from brain tissue comprising multiple cell types. It is therefore 
difficult to assess whether the transcriptional changes observed are directly attributable to those cells 
undergoing adult neurogenesis in the DG.  
However, animal models of neurogenesis have previously shown that transcriptional changes in 
neurogenic markers correlate well with changes in endogenous neurogenesis (Burger et al., 2008; 
Inoue et al., 2015; Juliandi et al., 2015). Our analyses of human transcriptomic datasets show that in 
the hippocampus, several neurogenic marker genes are differentially expressed between AD and 
healthy patients, and the expression pattern of these data identified by meta-profile analysis are in 
line with that of IHC experiments reviewed in this study. Overall, both IHC and transcriptomic analyses 
suggest that whilst the expression of proliferation marker is increased, late neurogenic markers are 
downregulated in the hippocampus in AD.  
We suggest that the identification of human-relevant markers of neurogenesis as well as 
investigations into transcriptomic changes and temporal expression of neurogenic markers at the 
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single-cell level would be imperative to better elucidate the changes occurring in the key player cell-
types of adult neurogenesis in AD.   
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5. Conclusions 
Taken together, the findings reviewed herein seem to suggest that numbers of neural progenitors are 
increased or unaltered in AD compared to controls. However, maturation of these progenitors into 
new neurons is compromised in late AD (Boekhoorn et al., 2006; Briley et al., 2016; Ekonomou et al., 
2015; Jin et al., 2004b; Li et al., 2008). This model also seems applicable at the transcriptional level 
(Fig. 4). Since most post-mortem human studies reviewed herein were carried out in the later stages 
of the disease (Braak V-VI), it is not possible to draw any conclusion with regards to alterations of 
neurogenesis at the early stages of AD. However, we can conclude that overall, the generation of fully 
functional new neurons is reduced in late Alzheimer’s disease. 
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Table and figure legends 
Table 1. 
Main findings of 13 studies on expression of neurogenic markers in post-mortem human 
neurodegenerative disease brain samples. The terms higher (↑), lower (↓) or unchanged (↔) used 
in the table refer to the corresponding changes in expression of neurogenic or proliferation markers 
relative to the control group within the study, as identified by the authors of the study themselves. 
AD: Alzheimer’s disease, NDAN: non-demented patients with Alzheimer’s neuropathology, CJD: 
Creutzfeldt-Jakob disease, PMD: postmortem delay, MMSE: mini mental state examination, SGZ: 
subgranular zone, ECL: ependymal cell layer, DG: dentate gyrus, WB: western blotting, IHC: 
immunohistochemistry, GCL: granule cell layer, SVZ: subventricular zone, ICC: immunocytochemistry, 
CERAD: Consortium to Establish a Registry for Alzheimer's Disease, APOE: Apolipoprotein E, CA: Cornu 
Ammonis. 
Table 2. 
A summary of the expression changes observed in AD compared to controls in the 13 different studies 
reviewed. The terms higher (↑), lower (↓) or unchanged (↔) used in the table refer to the 
corresponding changes in expression of neurogenic or proliferation markers relative to the control 
group within the study, as identified by the authors of the study themselves. SGZ: subgranular zone, 
ECL: ependymal cell layer, DG: dentate gyrus, WB: western blotting, IHC: immunohistochemistry, GCL: 
granule cell layer, EC: entorhinal cortex, SVZ: subventricular zone, NDAN: non-demented patients with 
Alzheimer’s neuropathology, AD: Alzheimer’s disease.  
Table 3. 
Filtering criteria for the 13 Alzheimer’s disease (AD) related articles yielded from the systematic 
search. 
Box 1. 
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List of neurogenesis and proliferation markers discussed within this review. 
Fig. 1. Diagrams showing the neurogenesis process in the dentate gyrus (DG) and the subventricular 
zone (SVZ) of the adult mammalian brain. The markers listed are those known to mark the 
corresponding five stages of the neuronal maturation process (primarily from rodent studies). RMS: 
rostral migratory stream, OB: olfactory bulb. 
Fig.2. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) (Moher et al., 
2009) flow diagram for systematic search and identification of studies meeting inclusion criteria for 
systematic review. Inclusion criteria were as follows: 1) studies evaluating post-mortem brain samples 
of a neurodegenerative disease, 2) studies measuring neurogenic markers and 3) studies including 
patient cases and non-demented controls. Exclusion criteria were as follows: 1) studies not in English; 
2) non-primary literature; 3) animal research; 4) non-immunohistochemical or western blotting 
analysis as primary outcome variables; 5) case studies without controls. 
Fig.3.  
 of the expression changes for the selected genes seen in various AD transcriptional profiles. The 
expression levels are scale according to 2
(𝑑−𝑐)
(𝑑+𝑐)
, where d and c are disease and control values. 
Fig.4. A) Graph showing changes in gene expression of neurogenic/proliferation markers across AD 
studies identified in the GEO human database. B) Graph showing changes in gene expression of 
neurogenic/proliferation markers in the hippocampus across early AD studies identified in the GEO 
human database. C) Graph showing changes in gene expression of neurogenic/proliferation markers 
in the hippocampus across late AD studies identified in the GEO human database. In A, B and C the 
bars correspond to the number of studies in which gene expression was upregulated (green area) or 
downregulated (red area) in AD for the individual genes. D) Graph showing the correlation of gene 
expression changes of neurogenic/proliferation markers with MMSE scores in AD study GSE1297. 
Genes with a negative correlative Z-score have a negative correlation with MMSE, and therefore, a 
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positive correlation with AD (red area) whilst genes with a positive correlative Z-score have a 
positive correlation with MMSE and a negative correlation with AD (green area). GFAP and CRMP1 
expression significantly correlated to moderate cognitive impairment (MMSE>15) and MKI67 
significantly correlated to mild cognitive impairment (MMSE>20). E) Graph showing the correlation 
of gene expression changes of neurogenic/proliferation markers with CDR scores (full range 0-5) in 
AD study GSE84422. F) Graph showing the correlation of gene expression changes of 
neurogenic/proliferation markers with CDR scores (range 0-2) in AD study GSE84422. In E and F, 
genes with a negative correlative Z-score have a negative correlation with CDR, and therefore, AD 
(red area), and genes with a positive correlative Z-score have a positive correlation with CDR and AD 
(green area). MMSE = Mini mental state examination. CDR = clinical dementia rating. 
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 Marker Full name  Expression  
GFAP Glial fibrillary acidic protein neural stem cells and astrocytes  
VIM vimentin 
expressed during transition from neuroepithelial cell to radial glia and persists 
during astrocyte development.  
Msi-1 Musashi-1 proliferating neural stem cells 
GFAPδ Glial fibrillary acidic protein - delta pluripotent neural cells 
SOX2 (sex determining region Y)-box 2 neural progenitor cells 
Nestin neuroectodermal stem cell marker 
intermediate filament protein, implicated in the radial growth of the axon. Can be 
expressed in glial cells following cerebral ischemia, traumatic brain injury, de-
afferentiation of the DG and neurotoxicity. 
NeuroD Neurogenic Differentiation 
a differentation factor for neurogenesis. Expressed in later stages of neuronal 
commitment.  
TUC-4 (CRMP-4) "Turned on after division" 
postmitotic neurons at the stage of initial differentiation and is associated with 
axonal outgrowth. Expressed in the growth cone.  
PSA-NCAM polysialyliated -Neural cell adhesion molecule 
Involved in neurite outgrowth and synaptogenesis. Expressed at later stages of 
neurogenesis including young postmitotic neurons. Important regulator of 
hippocampal plasticity.  
DCX doublecortin late mitotic neuronal precursors and early postmitotic neurons. 
β-III-tubulin / TuJ1 beta-III-tubulin 
immature postmitotic neurons and differentiated neurons and some mitotically 
active neuronal precursors. 
Calretinin 29k Calbindin 
immature postmitotic neurons. Mainly expressed during axonal and dendritic 
targeting. 
Calbindin-D28k Calcium-binding protein D28k mature dentate granule cells 
MAP2c Microtubule-associated protein 2 (Low molecular weight)  most prominently expressed in the developing brain.  
MAP2a,b Microtubule-associated protein 2 (High molecular weight)  mature neurons, reactive astrocytes 
HuC/D Elav-like proteins  
early and late postmitotic mature neurons. involved in the differentiation and/or 
maintenance of neurons.  
NeuN Feminizing Locus on X-3 early and late postmitotic neurons 
   
Proliferation markers   
PCNA Proliferating cell nuclear antigen present during G1/S phase of the cell cycle 
Ki-67 MK167/cellular marker for proliferation present during all active cycles of the cell cycle 
Alzheimer's disease (AD) 
       
 
 
Study number of cases, sex, Age 
(Mean±SD)  
PMD (Mean
±SD)  
Disease severity 
scale (Braak) 
MMSE 
(mean) 
Disease 
duration 
(years) 
Additional 
measures 
Neurogenic 
Marker 
measured 
Technique used and 
brain region studied 
Antibodies used Results 
(G
ill
ia
n
, e
t 
al
.,
 1
9
9
4
) 
WB 
Controls n=1, 71 
AD n=3, 73.67 
WB 
Controls 
24h 
AD 22h 
    
NCAM WB/ELISA 
Frontal cortex  
Temporal cortex  
hippocampus  
NCAM: Polyclonal antisera 
(Affinity Ltd., Nottingham, UK) 
1:3000 dilution  
 ↔ NCAM in AD (through 
all brain regions). 
  
ICC 
Controls n=unknown, 70 
± 14 
AD n=unknown, 80 ± 7 
ICC  
combined 
PMD of 31 ± 
3 h 
      
   
(M
ik
ko
n
en
, e
t 
al
.,
 1
9
9
9
) 
 
Controls n=10 (5m, 5f) 
71.1 ± 12.7 
AD n=12 (1m,11f) 82.4 ± 
10.9 
Controls 24.
0 ± 31.3h 
AD 4.3 ± 
1.7h 
Controls 0-I 
AD VI 
Controls 
N/A 
AD 3 ± 4.2 
Controls 0 y 
AD 9.9 ± 4.1 
y 
 
PSA-NCAM IHC  
DG 
CA1  
PSA-NCAM: Mouse monoclonal 
12E3(gifted from Dr. T. Seki, 
Japan) 1:800 
 
↑PSA-NCAM in AD in outer 
molecular layers and inner 
third of DG.  
↑PSA-NCAM in AD in some 
CA1 subfield sections 
↔ PSA-NCAM in GCL  
(J
in
, e
t 
al
.,
 2
0
0
4
) 
 
WB  
Controls n=7 (5m, 2f) 35.4    
Early AD n=3 (3m) 76.67  
Moderate AD n=3 (3m) 
79  
Severe AD n=3 (3m) 77.33 
WB 
Controls 
9.28h 
Early AD 
14h 
Moderate 
AD 15.67h 
Severe AD 
14.33h 
    
WB  
DCX  
PSANCAM  
NEuroD  
Tuc-4  
Calbindin  
WB 
hippocampus 
DCX: goat polyclonal (Santa 
Cruz Biotechnology; 1:200),  
PSA-NCAM: mouse monoclonal 
(Chemicon; 1:500),  
NeuN: mouse monoclonal 
(Chemicon; 1:250) 
TUC-4: rabbit polyclonal 
(Chemicon, 1:10,000),  
NeuroD: goat polyclonal (Santa 
Cruz Biotechnology; 1:200) 
Calbindin: mouse monoclonal 
(Oncogene Science; 1:10,000) 
WB 
↑DCX, PSA-NCAM, Tuc-4 
and NeuroD in AD 
hippocampus   
↔ in calbindin D28K and 
NeuN.  
  IHC  
Controls n=4 (3m, 1f) 66  
AD n=5 (1f, 4 unknown) 
74.8 
IHC 
Controls 
15.5h 
AD 11h 
    
IHC 
DCX  
Tuc-4 
IHC  
SGZ  
GCL  
 
 
IHC 
↑TUC4 and DCX in GCL in 
AD.  
Shrunken, dead DCX/TUC-4 
+ve cells observed in SGZ in 
AD and aged controls. 
DCX+ve cells observed in 
CA1 in AD. 
(Z
ia
b
re
va
, 
et
 a
l.,
 2
0
0
6
) 
 Controls n=7 (3m, 4f) 
79.67±3.93  
AD n= 7 (1m,6f) 
82.50±4.97 
Controls 
38±15.39h 
AD 
22.25±11.32
h 
Controls 2.17 
±1.47 
AD 5.17 ±0.98 
Controls 
ND 
AD 
9.83±8.33 
Controls 0 y 
AD  
3.92±2.38 y 
CERAD Msi-1 
nestin 
GFAP 
IHC 
SVZ 
ECL 
Msi-1: Rabbit polyclonal 
(Chemicon, 1:1000) 
Nestin: Rabbit polyclonal 
(Chemicon, 1:600) 
↑Nestin in SVZ in AD 
. ↔ in ECL.  
↓ in Msi-1 in SVZ in 
AD.  ↔ in ECL. 
↔GFAP in SVZ 
GFAP: Rabbit polyclonal 
(DakoCytomation, 1:4000) 
 Inverse correlation of Msi1 
immunoreactivity in SVZ 
with ChAT in temporal 
cortex. 
(B
o
ek
h
o
o
rn
, e
t 
al
.,
 2
0
0
6
) 
 
Controls n=10 (6m, 4f) 
67.1± 2.3 
AD n=9 (4m, 5f) 66.2± 2 
Controls 9.4
2± 5.55h 
AD 5.12± 
1.06h 
Controls 0-II 
AD V-VI 
 
AD 10.7 y fixation 
time 
Reisberg 
stage 
Brain 
weight 
APOE 
cause of 
death 
age of 
onset 
comorbidit
ies  
DCX 
GFAP 
Ki67 
IHC  
SGZ 
DG 
hilus 
CA 
Cortex  
DCX: Goat polyclonal (Santa 
Cruz Biotechnnology, 1:200) 
GFAP: mouse monoclonal clone 
6F2 (Monosan B.V, Uden, NL, 
1:10) 
Ki67: MIB-1 mouse monoclonal 
(DakoCytomation, 1:250) 
↑Ki67 in CA1-3 in presenile 
AD (mainly due to increases 
in glia-rich and blood 
vessel-rich areas) 
Ki67 immunoreactivity in 
neurons is limited to DG in 
presenile AD. 
↑GFAP in DG in presenile 
AD (astrogliosis) 
 ↔ DCX in presenile AD 
(SGZ, hilus) (highly variable 
immunostaining between 
subjects) 
(L
i, 
et
 a
l.,
 2
0
0
8
) 
 
Controls n=15 (6m,9f) 
83.6 ± 7.4 
AD n=14 (7m,7f) 79.4 ± 
10.9 
Controls 2.6 
± 0.6h 
AD 2.4 ± 
0.6h 
Controls I-III 
AD IV-VI 
  
CERAD, 
APOE 
genotype 
MAP2a/ b 
(mature 
markers)  
MAP2c 
(immature 
markers) 
IHC and insitu 
hybridization 
DG  
(+ cerebellum) 
MAP2a,b and MAP2a,b,c 
(Sigma-Aldrich, 1:200) 
 ↓ MAP2a,b in AD DG.  
↔ MAP2a,b,c (total) in AD 
DG.  
 
MAP2a mRNA levels 
decreased in AD DG. MAP2c 
mRNA levels unchanged in 
AD DG. No changes in 
cerebellum. 
(C
re
w
s,
 e
t 
al
.,
 2
0
1
0
) 
 
Controls, n=5, 87.0 ± 4.6     
early/moderate AD n=7, 
86.1 ± 1.7 severe AD n= 7, 
80.0 ± 1.9 
Controls 9.5 
± 3.5 h                    
early/moder
ate AD 11.8 
± 2.8h  
severe AD 
8.2 ± 0.8h 
Controls  0-I                     
early/moderate 
AD  I-II  
severe AD VI 
Controls 
28.5±0.9                     
early/mo
derate AD 
27.6±1.8 
severe AD 
5.8±4.2 
Controls 0 y 
early/moder
ate AD 
2.7±2.67 y 
severe AD 
10.2±1.4y 
Blessed 
score, 
Dementia 
rating 
scale,  
Brain 
weight, 
years of 
education 
DCX 
SOX2  
IHC 
SGZ 
DCX: goat polyclonal (Santa 
Cruz Biotechnology). 
SOX2: mouse monoclonal 
 
↓ DCX and SOX2 in severe 
AD DG. 
(associated with elevated 
levels of potential 
neurogenesis regulator 
BMP6) 
(P
er
ry
, e
t 
al
.,
 2
0
1
2
) 
 
Controls n=21 (8m, 13f) 
80.9±8.5 
AD n=20 (7m, 
13f) 81.2±7.0 
PMDs not 
given (said 
to be non-
significantly 
different 
between 
groups) 
Controls  0-III 
AD  IV-VI 
   
Msi-1 
Nestin  
DCX  
PSA-NCAM  
B-tubulin 
IHC 
SVZ 
SGZ 
GCL 
Msi-1: rabbit polyclonal, 
(Chemicon),  
Nestin: rabbit polyclonal, 
(Chemicon),  
DCX: rabbit polyclonal (Abcam) 
PSA-NCAM: mouse monoclonal 
(Dako, Glostru p,)  
β-III-tubulin: mouse monoclonal 
(Sigma). 
Msi-1 (rabbit polyclonal, 
Chemicon), nestin (rabbit 
polyclonal, Chemicon), PSA-
NCAM (mouse monoclonal, 
Dako, Glostru p, Denmark), 
ChAT (goat polyclonal, 
Chemicon), doublecortin 
(rabbit poyclonal, Abcam) 
and β-III-tubulin (mouse 
monoclonal, Sigma), 
respectively. 
  
 
(G
o
m
ez
-N
ic
o
la
, e
t 
al
.,
 2
0
1
4
) 
 
Controls for CJD n=10 
(5m, 5f) 20-35y range 
Controls for AD n=9 (5m, 
4f) 58-79y range 
CJD n=10 (5m, 5f) 20-34y 
AD n=10 (5m, 5f) 58-76y 
     
Ki67 
Calretinin 
SOX2 
IHC 
DG 
Rabbit anti-Ki67: (Abcam) 
Rabbit anti-Calretinin: 
(Millipore) 
Goat anti-Sox2: (Santa Cruz 
Biotechnologies) 
↑Ki67 and Calretinin in DG 
of AD and CJD 
 ↔ in SOX2 in DG of AD 
and CJD 
(E
ko
n
o
m
o
u
, e
t 
al
.,
 2
0
1
5
) 
 
Braak stage 0-II n=12 (7m, 
5f), 80.3 ± 8.4 (dementia 
n=3) 
Braak stage III-IV n=11 
(3m, 8f) 88.9 ± 8.2 
(dementia n=5) 
Braak stage V-VI n=5 (4m, 
1f) 86.8 ± 5.3 (dementia 
n=5) 
PMD given 
as median 
(IQR) 
Braak 0-II: 
17.5 (12-
28)h 
Braak III-IV: 
25 (7-27)h 
Braak V-VI: 
17.5 (9.5-
33)h 
 
n=12, 0-II  
n=11 ,  III-IV  
n=5,  V-VI 
      Nestin 
DCX 
PCNA 
HuC/D 
GFAP 
IHC 
SVZ 
ECL 
DG 
Nestin: Chemicon, 1:200 
DCX: Santa Cruz, 1:200 
PCNA: DAKO, 1:1000 
HuC/D: Invitrogen, 1:1000 
GFAP: DAKO, 1:6000 
 
 ↔Nestin in DG.  
↓HuC/D in DG in Braak V-
VI.  
↓GFAP in DG in Braak III-
IV. ↑GFAP in DG in Braak 
V-VI. 
↑DCX in DG in higher Braak 
stages.  
↔ all markers in SVZ and 
ECL 
(Significant positive 
correlation between new 
neurons and activated 
microglia and a negative 
correlation between new 
neurons and astrocytic cell 
numbers.) 
(B
ri
le
y,
 e
t 
al
.,
 2
0
1
6
) 
 
Controls n=4 (3f,1m), 74-
>89y range 
MCI n=3 (3f), ≥89y. 
AD n=6 (5f,1m), 67->89y 
range 
NDAN n=4 (3f,1m) >89y. 
Controls 2-
16h range 
MCI 4-20h 
range 
AD 3.3 – 
25h range 
NDAN 4.5-
48h range 
Controls I-II 
MCI II-V 
AD VI 
NDAN IV-VI 
Controls 
29-30 
MCI 20-25 
AD 0-15 
NDAN 26-
29 
  SOX2 
NeuN 
DG  Rabbit anti-SOX2 rabbit (Cell 
Signaling, 1:200 
mouse anti-NeuN (Millipore, 
1:1000).  
↑total SOX2+ cells in DG in 
NDAN (n.s. compared to 
controls, significantly 
higher than in AD and MCI) 
↑SOX2+/NeuN+ in DG in 
NDAN 
↓SOX2+/NeuN+ in DG in 
AD and MCI 
↑SOX2+/NeuN- in DG in 
NDAN and MCI 
↓SOX2+/NeuN- in DG in 
AD 
↔ total NeuN+ in AD, MCI 
and NDAN 
↔ NeuN+/SOX2- in AD, 
MCI and NDAN 
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9
9
4
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(B
o
e
kh
o
o
rn
, e
t 
al
.,
 2
0
0
6
) 
(L
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0
8
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0
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(P
er
ry
, e
t 
al
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0
1
2
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-N
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o
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, e
t 
al
.,
 
2
0
1
4
) 
(E
ko
n
o
m
o
u
, e
t 
al
.,
 2
0
1
5
) 
(B
ri
le
y,
 e
t 
al
.,
 2
0
1
6
) 
GFAP    ↔ (SVZ) ↑ (DG)     ↓ (DG-Braak III-
IV) 
↑ (DG-Braak V-
VI) 
↔ (SVZ) 
↔ (ECL) 
 
Msi-1    ↓ (SVZ) 
↔ (ECL) 
   ↓ (SGZ) 
↓ (GCL) 
↔ (SVZ) 
   
SOX2       ↓ (SGZ)  ↔ (DG)  ↑ NDAN (DG) 
↓AD (DG) 
Nestin    ↑ (SVZ) 
↔ (ECL) 
   ↑ (SGZ) 
↑ (GCL) 
↑ (SVZ) 
 ↔ (DG) 
↔ (SVZ) 
↔ (ECL) 
 
TUC-
4/CRMP-4 
  ↑ (GCL by IHC) 
↑ (hippocampus 
by WB) 
 
        
PSA-NCAM ↔ 
(Hippocampus 
by WB) 
↔ (GCL) 
↑ (CA1 
subfields, 
outer 
molecular 
layers and 
inner third 
of DG) 
 
↑ (hippocampus 
by WB) 
    ↑ (SGZ) 
↑ (GCL) 
↔ (SVZ) 
   
DCX   ↑ (GCL by IHC) 
↑ (hippocampus 
by WB) 
 ↔ (SGZ,hilus)  ↓ (SGZ) ↑ (GCL) 
↔ (SVZ, 
SGL) 
  
↑ (DG-Braak V-
VI) 
↔ (SVZ) 
 
↔ (ECL) 
 
Β-III-Tubulin        ↔ (SVZ, 
SGL, GL) 
 
   
Calretinin         ↑ (SGZ) 
 
  
Calbindin-
D28K 
  ↔ (hippocampus 
by WB) 
 
        
MAP2c      ↔ (total 
MAP2a,b,c in 
DG) 
     
MAP2a,b      ↓ (DG)      
HuC/D          ↓ (DG-Braak V-
VI) 
 
 
NeuN   ↔ (hippocampus 
by WB) 
 
       ↔ NDAN (DG) 
↔ AD (DG) 
[↑ 
SOX2+/NeuN+ 
cells in NDAN 
(DG)] 
 
 
 
Proliferation markers 
PCNA     
          
↔ double 
PCNA-HuC/D 
immunolabelling 
in DG/SVZ 
 
Ki-67     ↑ (CA1-3)       ↑ (SGZ)   
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
    
Study 
Are controls defined and age-
matched?  
Is a disease severity scale 
given?  
Are multiple neurogenic/proliferation 
markers used?  
Is any confounding 
pathology discussed 
in controls/patients?  
(Gillian, et al., 1994) IHC- x /WB-✓ control n=1 x x x 
(Mikkonen, et al., 
1999) ✓   ✓   x  x 
(Jin, et al., 2004) IHC- ✓/ WB- x  IHC-  x  /WB-✓ ✓   x 
(Ziabreva, et al., 
2006) ✓   ✓   ✓   x 
(Boekhoorn, et al., 
2006) ✓   ✓   ✓   ✓   
(Li, et al., 2008) ✓   ✓   x ✓   
(Crews, et al., 2010) ✓   ✓   ✓   x 
(Perry, et al., 2012) ✓   ✓   ✓   x 
(Gomez-Nicola, et al., 
2014) ✓   x ✓   x 
(Ekonomou, et al., 
2015) ✓   ✓   ✓   ✓   
(Briley, et al., 2016) ✓   ✓   ✓   x 
     
